SLC35F6: A Potential Drug Target Or Biomarker (G54978)

Target Name: SLC35F6

NCBI ID: G54978

SLC35F6: A Potential Drug Target Or Biomarker

SLC35F6 (TANGO9) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the TANGO family of proteins, which are known for their role in regulating cell signaling pathways. SLC35F6 has been shown to play a role in several physiological processes, including cell signaling, inflammation, and metabolism. As a result, SLC35F6 has potential as a drug target or biomarker.

SLC35F6 is a transmembrane protein that is expressed in a variety of tissues, including the brain, heart, and kidneys. It is a member of the TANGO family of proteins, which are known for their role in regulating cell signaling pathways. The TANGO family consists of four proteins: TANGO1, TANGO2, TANGO3, and SLC35F6. SLC35F6 is the latest member of the TANGO family to be identified and its function is still being fully understood.

SLC35F6 is involved in several physiological processes, including cell signaling, inflammation, and metabolism. It has been shown to play a role in regulating the activity of several signaling pathways, including the TGF-β pathway, the NF-kappa-B pathway, and the PI3K/Akt pathway. SLC35F6 is also involved in the regulation of inflammation, as it has been shown to play a role in the production of pro-inflammatory cytokines.

In addition to its role in cell signaling and inflammation, SLC35F6 is also involved in metabolism. It has been shown to play a role in the regulation of glucose metabolism, as it is involved in the uptake and storage of glucose in the liver. SLC35F6 is also involved in the regulation of lipid metabolism, as it is involved in the synthesis and storage of lipids in the liver.

SLC35F6 has also been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, studies have shown that SLC35F6 is involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. It is also involved in the regulation of several cardiovascular risk factors, including blood pressure, cholesterol, and smoking status.

Given its involvement in several physiological processes and its potential role in the development and progression of several diseases, SLC35F6 is an attractive drug target or biomarker. Studies have shown that SLC35F6 can be targeted with small molecules, antibodies, and other therapeutic agents. For example, several studies have shown that SLC35F6 can be inhibited by small molecules, such as inhibitors of the TGF-β pathway or the NF-kappa-B pathway. Similarly, several studies have shown that SLC35F6 can be targeted with antibodies, such as monoclonal antibodies (MCAs) or polyclonal antibodies (PCAs).

In conclusion, SLC35F6 is a protein that is involved in several physiological processes and has potential as a drug target or biomarker. Its function is still being fully understood, but its potential as a therapeutic agent is significant. Further research is needed to fully determine the role of SLC35F6 in cell signaling, inflammation, and metabolism, as well as its potential as a drug target or biomarker.

Protein Name: Solute Carrier Family 35 Member F6

Functions: Involved in the maintenance of mitochondrial membrane potential in pancreatic ductal adenocarcinoma (PDAC) cells. Promotes pancreatic ductal adenocarcinoma (PDAC) cell growth. May play a role as a nucleotide-sugar transporter

More Common Targets